Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Bellicum Pharmaceuticals (BLCM) PT Lowered to $25 at Citi Following Rimiducid Activation SwitchMarch 15, 2018 6:58 AM Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501March 13, 2018 7:00 AM